Cargando…

Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

BACKGROUND: Optimisation of dopaminergic therapy may alleviate fluctuation-related pain in Parkinson’s disease (PD). Opicapone (OPC) is a third-generation, once-daily catechol-O-methyltransferase inhibitor shown to be generally well tolerated and efficacious in reducing OFF-time in two pivotal trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhuri, K. Ray, Odin, Per, Ferreira, Joaquim J., Antonini, Angelo, Rascol, Olivier, Kurtis, Mónica M., Storch, Alexander, Bannister, Kirsty, Soares-da-Silva, Patrício, Costa, Raquel, Magalhães, Diogo, Rocha, José Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917369/ https://www.ncbi.nlm.nih.gov/pubmed/35279112 http://dx.doi.org/10.1186/s12883-022-02602-8

Ejemplares similares

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
por: Reichmann, Heinz, et al.
Publicado: (2020)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Opicapone for Parkinson’s disease
Publicado: (2023)

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Kwak, Nayoung, et al.
Publicado: (2022)

Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
por: Loureiro, Ana I., et al.
Publicado: (2021)

Absorption, metabolism and excretion of opicapone in human healthy volunteers
por: Loureiro, Ana I., et al.
Publicado: (2022)

Opicapone: A third generation COMT inhibitor
por: Greenwood, Jessica, et al.
Publicado: (2020)

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions
por: Ferreira, J. J., et al.
Publicado: (2019)

Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

Acute akathisia following initiation of opicapone: A case report
por: Baumgartner, Alexander J., et al.
Publicado: (2022)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease
por: Jost, Wolfgang H
Publicado: (2022)

Clinical Utility of Opicapone in the Management of Parkinson’s Disease: A Short Review on Emerging Data and Place in Therapy
por: Azevedo Kauppila, Linda, et al.
Publicado: (2021)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
por: Annus, Ádám, et al.
Publicado: (2017)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson’s disease
por: Löhle, Matthias, et al.
Publicado: (2022)

Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Singh, Alok, et al.
Publicado: (2021)

Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis
por: Xie, Luwen, et al.
Publicado: (2022)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Application of single wrist-wearable accelerometry for objective motor diary assessment in fluctuating Parkinson’s disease
por: Löhle, Matthias, et al.
Publicado: (2023)

Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Motor fluctuations and dyskinesias (diagnosis and management)
Publicado: (2011)

Characterization of Non‐Motor Fluctuations Using the Movement Disorder Society Non‐Motor Rating Scale
por: van Wamelen, Daniel Johannes, et al.
Publicado: (2022)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Editorial comments: treatment of motor fluctuations in Parkinson’s disease
por: Korczyn, Amos D.
Publicado: (2011)

Early Motor Fluctuations in a Patient with Striatonigral Degeneration
por: Yoshii, Fumihito, et al.
Publicado: (2016)

Nausea as a non-motor fluctuation in Parkinson’s disease
por: Weisbach, Emily, et al.
Publicado: (2022)

Gender differences in non-motor fluctuations in Parkinson’s disease
por: Donzuso, Giulia, et al.
Publicado: (2023)

Associations Between Fluctuations in Daytime Sleepiness and Motor and Non‐Motor Symptoms in Parkinson's Disease
por: Höglund, Arja, et al.
Publicado: (2020)

The Physiological Function of nNOS-Associated CAPON Proteins and the Roles of CAPON in Diseases
por: Xie, Wenshuo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bavlngfnaq3j6b5sklq3svqs41